CrownBio offers a collection large enough to be representative of the histological and genetic diversity seen in the patient population in ongoing clinical trials.
CrownBio’s newly established models have been trialed with a range of EGFR inhibitors – including I, II, and III generation TKIs as well as Erbitux® – and their poor response to therapy mirrors the...
“With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”
CrownBio clients will be now able to manage their internal patient-derived xenograft (PDX) portfolio on the model of CrownBio’s bespoke HuBase technology platform.
CrownBio intends to expand characterization, including next generation sequencing, of the models, and ultimately to develop new models resistant to current clinical therapies.
This expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants, and additional announcements on new models and capabilities at its UK facilities
Working at the forefront of SCLC research, Crown Bioscience developed the HuPrime® and PDXact™ Jumpstart collections of SCLC models, which are the most comprehensive collection of commercially avai...
Using clinically-relevant models, Crown Bioscience helps researchers make the best decisions to speed the optimum drug candidates to clinical development.
9 of 11
Receive JSR Life Sciences news on your RSS reader.
